COG NCTN Network Group Operations Center - Year 10 STAR Act COG) Outcomes & Survivorship (LTE) Committee

COG NCTN 网络集团运营中心 - 第 10 年 STAR 法案 COG) 结果

• 批准号: 10918928
• 负责人: Douglas S. Hawkins
• 金额: $ 324.3万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10918928
• 关键词: 1 year old; Acceleration; Acute; Acute Myelocytic Leukemia; Adolescent; Australia; Brain Stem Glioma; Canada; Cancer Center; Cancer Patient; Caring; Cause of Death; Cell Therapy; Child; Child Support; Childhood; Childhood Leukemia; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Collection; Communities; Complication; Country; Development; Diagnosis; Disease; Dose; Eligibility Determination; Enrollment; Ensure; Family; Foundations; Functional disorder; Generations; Goals; Hormonal; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; Knowledge; Laboratories; Late Effects; Lead; Malignant Childhood Neoplasm; Malignant Neoplasms; Methods; Mission; Molecular; Morbidity - disease rate; National Cancer Institute; National Clinical Trials Network; Neuroblastoma; New Zealand; Organ; Outcome; Patients; Pediatric Hospitals; Pediatric Oncology Group; Pharmaceutical Preparations; Population Heterogeneity; Population Research; Positioning Attribute; Productivity; Prognosis; Quality of life; Rare Diseases; Research; Research Personnel; Scientist; Second Primary Cancers; Site; Survival Rate; Survivors; Tissues; Translational Research; United States; Universities; Work; anticancer research; cancer diagnosis; cancer therapy; chemotherapy; childhood cancer survivor; clinical translation; design; experience; health related quality of life; high risk; improved; improved outcome; innovation; member; multidisciplinary; novel therapeutic intervention; operation; organizational structure; reproductive; small molecule; success; survivorship; translational study

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center, clinician-scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

项目概要 自从 60 多年前引入化疗治疗儿童白血病以来， 儿童癌症的预后显着改善 儿童癌症的总体 5 年生存率 其中许多在化疗前时代都是致命的，但现在有 84% 的儿童出现了进展。 然而，癌症的发生受到限制，大约 50% 的儿童患有急性髓性白血病，50% 的高危神经母细胞瘤儿童和超过 90% 的脑干胶质瘤儿童仍在死亡 在美国，癌症仍然是导致 1 岁以上儿童死亡的主要原因。 此外，癌症治疗的后期影响，包括永久性器官和组织损伤， 荷尔蒙和生殖功能障碍以及第二种癌症受到特别关注，超过 40% 500,000 名儿童癌症幸存者（估计截至 2020 年）经历了以下显着的健康相关质量 因此，尽管我们取得了进步，但新的治疗方法仍在不断发展。 治疗方法必须成为儿童癌症基础、转化和临床研究人员的首要任务。 儿童肿瘤学小组 (COG)，世界上最大的专门致力于儿童和癌症研究的组织 COG 的多学科研究团队成立于 20 年前。 拥有 9,000 多名会员，在 220 多家领先的儿童医院、大学和 该提案针对 COG，作为国家癌症研究所 (NCI) 国家临床试验的一部分。 网络（NCTN），继续其协作研究工作，支持改善结果的使命 针对所有癌症儿童，COG 将为癌症儿童设计并开展临床转化研究。 它建立在对儿科恶性肿瘤分子基础的日益了解的基础上，并且具有最高的 使用适合罕见疾病研究的创新临床试验设计的潜力， 我们将研究新的治疗方法，包括但不限于靶向小分子药物， 重要的是，COG 研究组合还包括临床试验。 专注于改善癌症儿童和儿童癌症幸存者的生活质量。 美国90%被诊断患有癌症的儿童在COG成员机构接受治疗，COG有能力 为不同的癌症儿童及其家人提供参与创新项目的机会 这项研究工作包括收集和注释所有儿童的生物样本。 与癌症一起，为发现提供基础并加速最有前途的研究工作 该提案是为了支持 COG 网络运营中心， 开发和开展研究的临床医生科学家，以及通过注册参与的会员站点 符合资格的科目。